Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to 22.66%.

  • Gyre Therapeutics' EBITDA Margin rose 60500.0% to 22.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.22%, marking a year-over-year increase of 837000.0%. This contributed to the annual value of 15.28% for FY2024, which is 745400.0% up from last year.
  • Per Gyre Therapeutics' latest filing, its EBITDA Margin stood at 22.66% for Q3 2025, which was up 60500.0% from 8.11% recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' EBITDA Margin peaked at 39.84% during Q3 2023, and registered a low of 1851.51% during Q1 2022.
  • Its 5-year average for EBITDA Margin is 426.11%, with a median of 8.11% in 2025.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -14985500bps in 2021, then soared by 18782400bps in 2023.
  • Quarter analysis of 5 years shows Gyre Therapeutics' EBITDA Margin stood at 832.5% in 2021, then surged by 97bps to 22.13% in 2022, then tumbled by -1425bps to 337.53% in 2023, then soared by 101bps to 2.39% in 2024, then surged by 850bps to 22.66% in 2025.
  • Its last three reported values are 22.66% in Q3 2025, 8.11% for Q2 2025, and 10.3% during Q1 2025.